Soleus Capital Master Fund, L.P. 13D and 13G filings for Terns Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-11 4:00 pm Purchase | 2024-12-31 | 13G | Terns Pharmaceuticals, Inc. TERN | Soleus Capital Master Fund, L.P. | 8,142,500 9.600% | 1,918,956 (+30.83%) | Filing |
| 2024-11-14 3:30 pm Purchase | 2024-09-30 | 13G | Terns Pharmaceuticals, Inc. TERN | Soleus Capital Master Fund, L.P. | 6,223,544 7.300% | 2,882,424 (+86.27%) | Filing |
| 2024-06-07 08:30 am Purchase | 2024-06-06 | 13G | Terns Pharmaceuticals, Inc. TERN | Soleus Capital Master Fund, L.P. | 3,341,120 5.200% | 3,341,120 (New Position) | Filing |